Interleukin-2 immunotherapy action on innate immunity cells in peripheral blood and tumoral tissue of pancreatic adenocarcinoma patients

Langenbeck's Archives of Surgery

Volumn 394, Issue 1, 2009, Pages 115-121

  Degrate, Luca ^a   Nobili, Cinzia ^a   Franciosi, Claudio ^a   Caprotti, Roberto ^a   Brivio, Fernando ^a   Romano, Fabrizio ^a   Leone, Biagio Eugenio ^a   Trezzi, Rosangela ^a   Uggeri, Franco ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

Eosinophilic tissue infiltration; Eosinophils; Interleukin 2; Natural killer cells; Pancreatic adenocarcinoma

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ARTICLE; BLOOD; BLOOD CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FEVER; HISTOPATHOLOGY; HUMAN; HYPOTENSION; IMMUNOTHERAPY; INJECTION SITE REACTION; INNATE IMMUNITY; LOW DRUG DOSE; MALE; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, PANCREATIC DUCTAL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; EOSINOPHILS; FEMALE; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; KILLER CELLS, NATURAL; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PANCREATECTOMY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; RECOMBINANT PROTEINS;

EID: 55849105191     PISSN: 14352443     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00423-008-0393-4     Document Type: Article

References (53)

1. Cruickshank AH, Benbow EW (1995) Pathology of the pancreas, 2nd edn. Springer, London
2. S Rosewicz B Wiedenmann 1997 Pancreatic carcinoma Lancet 15 786 792
3. CJ Yeo JL Cameron 1998 Prognostic factors in ductal pancreatic cancer Langenbecks Arch Surg 383 129 133
4. HG Smeenk TC Tran J Erdmann CH van Eijck J Jeekel 2005 Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist? Langenbecks Arch Surg 390 94 103 doi:10.1007/s00423-004- 0476-9
5. DT Fearon RM Locksley 1996 The instructive role of innate immunity in the acquired immune response Science 272 50 54 doi:10.1126/science.272.5258.50
6. P Lissoni S Viviani A Santoro 1989 Serum levels of Interleukin-2 in cancer patients: preliminary considerations Int J Biol Markers 4 203 206
7. M Maltoni M Pirovano O Nanni M Marinari M Indelli A Gramazio 1997 Biological indices predictive of survival in 519 Italian terminally ill cancer patients. Italian Multicenter and Study Group on Palliative Care J Pain Symptom Manage 13 1 9 doi:10.1016/S0885-3924(96)00265-5
8. W von Bernstorff M Voss S Freichel A Schmid I Vogel C Johnk 2001 Systemic and local immunosuppression in pancreatic cancer patients Clin Cancer Res 7 3)(Suppl 925s 932s
9. JM Plate JE Harris 2000 Immune cell functions in pancreatic cancer Crit Rev Immunol 20 375 392
10. RE Pollock E Lotzova SD Stanford 1991 Mechanism of surgical stress impairment of human perioperative natural killer cell cytotoxicity Arch Surg 126 338 342
11. MB Constantian JO Menzoian RB Nimberg K Schmid JA Mannick 1977 Association of a circulating immunosuppressive polypeptide with operative and accidental trauma Ann Surg 185 73 77 doi:10.1097/00000658-197701000-00012
12. TWJ Lennard BK Shenton A Borzotta PK Donnelly M White LM Gerrie 1985 The influence of surgical operations on components of the human immune system Br J Surg 72 771 776 doi:10.1002/bjs.1800721002
13. CD Griffith RC Rees A Platts A Jermy J Peel K Rogers 1984 The nature of enhanced natural killer lymphocyte cytotoxicity during anaesthesia and surgery in patients with benign disease and cancer Ann Surg 200 753 758 doi:10.1097/00000658-198412000-00014
14. T Akiyoshi F Koba S Arinaga S Miyazaki T Wada H Tsuji 1985 Impaired production of interleukin-2 after surgery Clin Exp Immunol 59 45 49
15. M Prochazka F Vyhnanek M Jira J Streicek 1987 Effect of interleukin-2 on peripheral blood mononuclear cells in severity injured patients Acta Chir Scand 153 401 404
16. F Brivio P Lissoni D Mancini E Tisi G Tancini S Barni 1991 Effect of antitumor surgery on soluble interleukin-2 receptor serum levels Am J Surg 161 466 469 doi:10.1016/0002-9610(91)91113-W
17. J Hamid J Bancewicz R Brown C Ward MH Irving WL Ford 1984 The significance of changes in blood lymphocyte populations following surgical operations Clin Exp Immunol 56 49 57
18. F Brivio P Lissoni G Alderi S Barni F Lavorato L Fumagalli 1996 Preoperative interleukin-2 subcutaneous immunotherapy may prolong the survival time in advanced colorectal cancer patients Oncology 53 263 268
19. KA Smith 1988 Interleukin-2: inception, impact, and implications Science 240 1169 1176 doi:10.1126/science.3131876
20. F Brivio P Lissoni MS Perego A Dissoni L Fumagalli 2001 Abrogation of surgery-induced IL-6 hypersecretion by presurgical immunotherapy with IL-2 and its importance in the prevention of postoperative complications J Biol Regul Homeost Agents 15 370 374
21. W Jeal K Goa 1997 Aldesleukin (recombinant interleukin-2): a review of its pharmacological properties, clinical efficacy and tolerability in patients with renal cell carcinoma BioDrugs 7 285 317
22. E Angevin D Valteau-Couanet F Farace PY Dietrich A Lecesne F Triebel 1995 Phase I study prolonged low-dose subcutaneous recombinant interleukin-2 (IL-2) in patients with advanced cancer J Immunother Emphasis Tumor Immunol 18 188 195
23. A Lindemann P Brossart K Hoffken M Flasshove D Voliotis V Diehl 1993 Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase-IB study Cancer Immunol Immunother 37 307 315 doi:10.1007/BF01518453
24. A Nicolini PA Mancini P Ferrari L Anselmi A Sagripanti A Carpi 1996 Immunological and side effects of low sc recombinant interleukin-2 dose in addition to conventional treatment in relapsed breast and colorectal cancer patients Biomed Pharmacother 50 344 349 doi:10.1016/S0753-3322(96)89666-1
25. NJ Meropol M Porter LE Blumenson MJ Lindemann RP Perez L Vaickus 1996 Daily subcutaneous injection of low-dose interleukin-2 expands natural killer cells in vivo without significant toxicity Clin Cancer Res 2 669 677
26. F Brivio P Lissoni E Tisi L Erba S Barni G Tancini 1992 Effects of a preoperative therapy with IL-2 on surgery induced lymphocytopenia in cancer patients Oncology 49 215 218
27. DJ Deehan SD Heys J Ashby O Eremin 1995 Interleukin-2 (IL-2) augments host cellular immune reactivity in the perioperative period in patients with malignant disease Eur J Surg Oncol 21 16 22 doi:10.1016/S0748-7983(05)80061-7
28. J Nieken DT Sleijfer J Buter L de Leij NH Mulder 1996 Outpatient based subcutaneous interleukin-2 momotherapy in advanced renal cell carcinoma: an update Cancer Biother Radiopharm 11 289 295
29. M Guida I Abbate A Casamassima MD Musci A Latorre V Lorusso 1995 Long-term subcutaneous recombinant interleukin-2 as maintenance therapy: biological effects and clinical implications Cancer Biother 10 195 203
30. AB Miller B Hoogstraten M Staquet A Winkler 1981 Reporting results of cancer treatment Cancer 47 207 214
31. S Kim K Iizuka HL Aguila IL Weissman WM Yokoyama 2000 In vivo natural killer cell activities revealed by natural killer cell-deficient mice Proc Natl Acad Sci U S A 97 2731 2736 doi:10.1073/pnas.050588297
32. HF Pross E Lotzova 1993 Role of natural killer cells in cancer Nat Immunol 12 279 292
33. F Lechin B Van Der Djis 2004 Natural killer cells activity and neuroimmunological treatment of cancer Clin Cancer Res 10 8120 8121 doi:10.1158/1078-0432.CCR-04-1508
34. DTW Wong SM Bowen A Elovic GT Gallagher PF Weller 1999 Eosinophil ablation and tumor development Oral Oncol 35 496 501 doi:10.1016/S1368-8375(99) 00023-8
35. ME Wallace MJ Smyth 2005 The role of natural killer cells in tumor control-effectors and regulators of adaptive immunity Springer Semin Immunopathol 27 49 64 doi:10.1007/s00281-004-0195-x
36. SA Rosenberg 2001 Progress in the development of immunotherapy for the treatment of patients with cancer J Intern Med 250 462 475 doi:10.1046/j.1365- 2796.2001.00911.x
37. K Cerea F Romano A Ferrari Bravo V Motta F Uggeri F Brivio 2001 Phase IB study on prevention of surgery-induced immunodeficiency with preoperative administration of low-dose subcutaneous interleukin-2 in gastric cancer patients J Surg Oncol 78 32 37 doi:10.1002/jso.1120
38. P Nichols CW Ramsden U Ward PC Sedman JN Primrose 1992 Perioperative immunotherapy with recombinant interleukin 2 in patients undergoing surgery for colorectal cancer Cancer Res 52 5765 5769
39. JS Miller 2001 The biology of natural killer cells in cancer, infection and pregnancy Exp Hematol 29 1157 1168 doi:10.1016/S0301-472X(01)00696-8
40. L Rivoltini V Viggiano S Spinazze A Santoro MP Colombo K Takatsu 1993 In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin-2. Role of interleukin 5 Int J Cancer 54 5 887 doi:10.1002/ijc.2910540528
41. NJ Meropol GM Barresi TA Fehniger J Hitt M Franklin MA Caligiuri 1998 Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing Cancer Immunol Immunother 46 318 326 doi:10.1007/s002620050493
42. TA Fehniger EM Bluman MM Porter E Mrozer MA Cooper JB Van Deusen 2000 Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy J Clin Invest 106 117 124 doi:10.1172/JCI6218
43. P Lissoni 1997 Effects of low-dose recombinant interleukin-2 in human malignancies Cancer J Sci Am 3 suppl 1 S115 S120
44. J Brittenden SD Heys J Ross O Eremin 1996 Natural killer cells and cancer Cancer 77 1226 1243
45. RT Davey DG Chaitt SC Piscitelli M Wells JA Kovacs RE Walker 1997 Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons J Infect Dis 175 781 789
46. JW Uhr RH Scheuermann NE Street ES Vitetta 1997 Cancer dormancy: opportunities for new therapeutic approaches Nat Med 3 505 509 doi:10.1038/nm0597-505
47. C Buzio S Andrulli R Santi L Pavone R Passalacqua D Potenzoni 2001 Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma Cancer 92 2286 2296
48. G Bovo F Brivio A Brenna L Fumagalli P Perego O Brivio 1995 Pre-operative Interleukin-2 immunotherapy induces eosinophilic infiltration in colorectal neoplastic stroma Pathologica 87 2 135 138
49. K Iwasaki M Torisu T Fujimura 1986 Malignant tumor and eosinophils. I. Prognostic significance in gastric cancer Cancer 58 1321 1327
50. MJ Fernandez-Acenero M Galindo-Gallego J Sanz A Aljama 2000 Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma Cancer 88 1544 1548
51. ID Nagtegaal CA Marijnen EK Kranenbarg A Mulder-Stapel J Hermans CJ van de Velde 2001 Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect-a histopathological and immunohistochemical study BMC Cancer 1 1 7 doi:10.1186/1471-2407-1-7
52. S Ishigami S Natsugoe K Tokuda A Nakajo X Che H Iwashige 2000 Prognostic value of intratumoral natural killer cells in gastric carcinoma Cancer 88 577 583
53. HJ Nielsen U Hansen IJ Christensen CM Reimert N Brunner F Moesgaard 1999 Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue J Pathol 189 487 495